Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
Amylyx Pharmaceuticals, Inc. (AMLX) had Receiveable Turnover of 9.51 for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
$380.79M |
|
$49.27M |
|
$25.44M |
|
$355.35M |
|
$341.98M |
|
$38.80M |
|
$15.49M |
|
$54.30M |
|
$54.30M |
|
$49.27M |
|
$49.27M |
|
$49.27M |
|
$49.27M |
|
$38.80M |
|
$29.95M |
|
67.23M |
|
69.99M |
|
$0.73 |
|
$0.70 |
|
| Balance Sheet Financials | |
$464.67M |
|
$2.69M |
|
$52.79M |
|
$517.45M |
|
$82.04M |
|
-- |
|
$1.98M |
|
$84.02M |
|
$433.43M |
|
$433.43M |
|
$433.43M |
|
67.71M |
|
| Cash Flow Statement Financials | |
$11.92M |
|
$92.05M |
|
$3.54M |
|
$63.24M |
|
$170.92M |
|
$107.67M |
|
$37.16M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.66 |
|
-- |
|
-- |
|
-- |
|
-- |
|
93.32% |
|
10.19% |
|
10.19% |
|
7.87% |
|
14.26% |
|
12.94% |
|
$10.68M |
|
-- |
|
-- |
|
-- |
|
0.74 |
|
0.66 |
|
|
Receiveable Turnover |
9.51 |
38.39 |
|
11.37% |
|
11.37% |
|
9.52% |
|
11.37% |
|
$6.40 |
|
$0.15 |
|
$0.17 |
|